Phillips WD - Search Results

1

Guidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravis.

Phillips WD, Christadoss P, Losen M, Punga AR, Shigemoto K, Verschuuren J, Vincent A. Phillips WD, et al. Exp Neurol. 2015 Aug;270:29-40. doi: 10.1016/j.expneurol.2014.12.013. Epub 2014 Dec 24. Exp Neurol. 2015. PMID: 25542979

2

Electrophysiological analysis of neuromuscular synaptic function in myasthenia gravis patients and animal models.

Plomp JJ, Morsch M, Phillips WD, Verschuuren JJ. Plomp JJ, et al. Among authors: phillips wd. Exp Neurol. 2015 Aug;270:41-54. doi: 10.1016/j.expneurol.2015.01.007. Epub 2015 Jan 23. Exp Neurol. 2015. PMID: 25620417 Review.

3

Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms.

Phillips WD, Vincent A. Phillips WD, et al. F1000Res. 2016 Jun 27;5:F1000 Faculty Rev-1513. doi: 10.12688/f1000research.8206.1. eCollection 2016. F1000Res. 2016. PMID: 27408701 Free PMC article. Review.

4

Muscle specific kinase autoantibodies cause synaptic failure through progressive wastage of postsynaptic acetylcholine receptors.

Morsch M, Reddel SW, Ghazanfari N, Toyka KV, Phillips WD. Morsch M, et al. Among authors: phillips wd. Exp Neurol. 2012 Oct;237(2):286-95. doi: 10.1016/j.expneurol.2012.06.034. Epub 2012 Jul 10. Exp Neurol. 2012. PMID: 22789393

5

Mouse models of myasthenia gravis.

Ban J, Phillips WD. Ban J, et al. Among authors: phillips wd. Curr Pharm Des. 2015;21(18):2468-86. doi: 10.2174/1381612821666150316123233. Curr Pharm Des. 2015. PMID: 25777761 Review.

6

Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.

Cole RN, Reddel SW, Gervásio OL, Phillips WD. Cole RN, et al. Among authors: phillips wd. Ann Neurol. 2008 Jun;63(6):782-9. doi: 10.1002/ana.21371. Ann Neurol. 2008. PMID: 18384168

7

Clinical and scientific aspects of muscle-specific tyrosine kinase-related myasthenia gravis.

Reddel SW, Morsch M, Phillips WD. Reddel SW, et al. Among authors: phillips wd. Curr Opin Neurol. 2014 Oct;27(5):558-65. doi: 10.1097/WCO.0000000000000136. Curr Opin Neurol. 2014. PMID: 25159928 Review.

8

Effects of the ß2-adrenoceptor agonist, albuterol, in a mouse model of anti-MuSK myasthenia gravis.

Ghazanfari N, Morsch M, Tse N, Reddel SW, Phillips WD. Ghazanfari N, et al. Among authors: phillips wd. PLoS One. 2014 Feb 5;9(2):e87840. doi: 10.1371/journal.pone.0087840. eCollection 2014. PLoS One. 2014. PMID: 24505322 Free PMC article.

9

The mouse passive-transfer model of MuSK myasthenia gravis: disrupted MuSK signaling causes synapse failure.

Ghazanfari N, Trajanovska S, Morsch M, Liang SX, Reddel SW, Phillips WD. Ghazanfari N, et al. Among authors: phillips wd. Ann N Y Acad Sci. 2018 Jan;1412(1):54-61. doi: 10.1111/nyas.13513. Epub 2017 Nov 10. Ann N Y Acad Sci. 2018. PMID: 29125188 Review.

10

Patient autoantibodies deplete postsynaptic muscle-specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice.

Cole RN, Ghazanfari N, Ngo ST, Gervásio OL, Reddel SW, Phillips WD. Cole RN, et al. Among authors: phillips wd. J Physiol. 2010 Sep 1;588(Pt 17):3217-29. doi: 10.1113/jphysiol.2010.190298. Epub 2010 Jul 5. J Physiol. 2010. PMID: 20603331 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

167 results

Search Page

Filters